Department of Physical Medicine and Rehabilitation Sports Medicine Center, Mayo Clinic Rochester, Minnesota.
Clin J Sport Med. 2014 Jan;24(1):88-9. doi: 10.1097/JSM.0000000000000063.
To compare the effectiveness of injections of platelet-rich plasma (PRP) compared with focused extracorporeal shock-wave therapy (ESWT) among athletes with chronic patellar tendinopathy (jumper's knee).
Randomized controlled single-center trial, with 12 months of follow-up.
Tertiary-level care in Rome, Italy. Patients were recruited from January 2009 to May 2011.
Patients who received a diagnosis of jumper's knee from a participating physician were recruited into the study (n = 46). Inclusion criteria were chronic (≥6 months), unilateral, proximal patellar tendinopathy in a recreational or elite athlete confirmed by ultrasound (US); prior failed nonoperative management that concluded ≥12 weeks prior to study entry; and ages 18 to 50 years. Exclusion criteria were coexisting knee lesions, systemic disorders, knee surgery or corticosteroid injection in the previous 3 months, and contraindications to PRP treatment.
Patients in the PRP group (n = 23) received 2 US-guided injections separated by 1 week and directed at the affected tendon portion. Each injection consisted of 2 mL of nonactivated, autologous PRP extracted from a single centrifugation of 10-mL blood and administered by a trained physician via a 22-guage needle. Patients in the focused ESWT group (n = 23) received 3 treatments (2400 impulses at 0.17-0.25 mJ/mm per session) separated by 48 to 72 hours. Treatments were guided by inline US and administered by 1 experienced operator. No local anesthesia was used in either group. One week later, both groups began a conventional stretching and strengthening program for 2 weeks. At 4 weeks, patients gradually resumed normal activities and sports, as tolerated.
At 2, 6, and 12 months after treatment, patients were assessed by a single investigator, blinded to group assignment. The main measure was the Italian version of the Victorian Institute of Sports Assessment-Patella (VISA-P) questionnaire, which evaluates severity of symptoms, function, and ability to participate in sport. A 10-cm visual analog scale (VAS) was used to assess pain while doing 5 single-leg squats. Patients also assessed their response to treatment on the Blazina scale (excellent to poor). No patients were lost to follow-up
During the 12-month follow-up period, VISA-P scores for both groups improved significantly from baseline (55.3 for PRP, 56.1 for ESWT), although the PRP group had greater improvement at 6 months (86.7 vs 73.7; P = 0.014) and 12 months (91.3 vs 77.6; P = 0.026). Pain scores during 5 single-leg squats demonstrated similar findings. At 12 months a greater proportion of patients in the PRP group rated their response to treatment as good or excellent (PRP, 91.3% vs ESWT, 60.8%; P = 0.035), although at earlier follow-ups the groups did not differ. Both the injections and ESWT caused transient discomfort. No patient had surgery during follow-up.
Athletes with chronic patellar tendinopathy responded positively to both PRP injection and ESWT. However, the PRP-treated patients demonstrated significantly greater improvements in VISA-P and pain scores by 6 months and significantly better functional outcomes and satisfaction based on a modified Blazina scale, at 12 months.
比较富血小板血浆(PRP)注射与聚焦体外冲击波疗法(ESWT)在慢性髌腱病(跳跃膝)运动员中的疗效。
随机对照单中心试验,随访 12 个月。
意大利罗马的三级护理。从 2009 年 1 月至 2011 年 5 月招募患者。
接受参与医生诊断为跳跃膝的患者被招募入组(n = 46)。纳入标准为慢性(≥6 个月)、单侧、经超声(US)证实的近端髌腱病的娱乐或精英运动员;先前失败的非手术治疗结束≥12 周前进入研究;年龄 18 至 50 岁。排除标准为并存膝损伤、全身疾病、膝关节手术或 3 个月内皮质类固醇注射以及 PRP 治疗禁忌证。
PRP 组(n = 23)患者接受 2 次 US 引导下注射,间隔 1 周,针对受累肌腱部位。每次注射包括 2 毫升非激活的、自体 PRP,从 10 毫升血液的单次离心中提取,由经过培训的医生通过 22 号针给药。聚焦 ESWT 组(n = 23)患者接受 3 次治疗(每次 0.17-0.25 mJ/mm 脉冲 2400 个),间隔 48 至 72 小时。治疗由在线 US 引导,由 1 名经验丰富的操作员进行。两组均不使用局部麻醉。治疗后 1 周,两组均开始进行为期 2 周的常规拉伸和强化训练。4 周时,患者逐渐恢复正常活动和运动,根据耐受情况进行。
治疗后 2、6 和 12 个月,由 1 名单盲组分配的研究员对患者进行评估。主要测量指标是意大利版维多利亚运动评估-髌腱(VISA-P)问卷,该问卷评估症状严重程度、功能和参与运动的能力。使用 10 厘米视觉模拟量表(VAS)评估 5 次单腿蹲时的疼痛。患者还根据 Blazina 量表评估他们对治疗的反应(从极好到差)。无患者失访。
在 12 个月的随访期间,两组的 VISA-P 评分均从基线显著改善(PRP 组为 55.3,ESWT 组为 56.1),尽管 PRP 组在 6 个月(86.7 对 73.7;P = 0.014)和 12 个月(91.3 对 77.6;P = 0.026)时改善更大。5 次单腿蹲时的疼痛评分也有类似发现。在 12 个月时,PRP 组有更大比例的患者对治疗反应评价为良好或优秀(PRP 组为 91.3%,ESWT 组为 60.8%;P = 0.035),尽管在早期随访时两组没有差异。注射和 ESWT 均引起短暂不适。在随访期间没有患者接受手术。
慢性髌腱病患者对 PRP 注射和 ESWT 均有积极反应。然而,PRP 治疗患者在 6 个月时 VISA-P 和疼痛评分显著改善,在 12 个月时根据改良 Blazina 量表,功能结局和满意度显著更好。